Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X
Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X
复制标题
DOI：
10.1046/j.1365-2141.1997.3113127.x
复制
发表时间：
1997-09-01
影响因子：
6.5
通讯作者：
Richards, SM
中科院分区：
文献类型：
--
作者：
Chessells, JM;Harrison, G;Richards, SM
在740例接受MRC UKALL X治疗的淋巴细胞白血病儿童队列中，研究了持续（维持）治疗期间药物处方剂量与骨髓抑制程度和随后的无事件生存率之间的关系。女孩、年幼儿童和接受强化治疗的患者，被处方的巯基嘌呤剂量较低，更容易出现血小板减少症，治疗中断的次数也更多。有一次或多次中性粒细胞减少症发作的儿童，
The relationship between the prescribed dose of drugs during continuing (maintenance) therapy the degree of marrow suppression caused, and subsequent event-free survival was examined in a cohort of 740 children with lymphoblastic leukaemia treated on MRC UKALL X. Girls, younger children, and patients who had received intensification treatment, were prescribed lower doses of mercaptopurine, became neutropenic more readily, and had more interruptions of treatment. Children who had one or more episodes of neutropenia with a count of